At the end of Jan 2026, Mike Exton ran the Nasdaq Closing Bell to celebrate Lexicon Pharmaceuticals' 30th anniversary. A recent positive end-of-Phase 2 meeting with the FDA now positions pilavapadin to advance into Phase 3 trials. At JPM 2026, Mike caught up with Onyx and delivered a clear
"85% of failures are us having failed the molecule, not the molecule having not delivered."
Capital is available, but only for companies with clean data, clear differentiation, and a believable commercial path.
A fully funded pharma study plus multiple R&D collaborations signals rising strategic pull.
Cema-cel is already in the pivotal Phase 2 ALPHA3 frontline lymphoma trial, with manufacturing capacity sized for tens of thousands of annual doses (up to ~60,000 across products).
Nuvation is gaining real momentum after its first FDA approval, with IBTROZI now treating a growing number of patients with ROS1-positive lung cancer.
The British biotech recently secured a £5.5 million pre-Series A round to advance their lead asset, Myo-004, toward clinical candidate selection.
Fresh momentum from Jefferies and a new $150 million non-dilutive financing has extended its runway into 2027.
What if the key to curing blindness wasn't targeting individual genes, but entire genetic networks?
Lexicon's latest drug for obesity and weight management has a novel mechanism and is backed by Novo Nordisk.
Allucent is a CRO which has overseen many therapeutics through to FDA approval.
Ever thought a probiotic could help manage blood sugar by stimulating GLP-1?
Can Cellares bring down the cost of some of the most expensive new therapies on the market?
Blood tests for cancer are here, and Guardant Health is leading the charge.
